Catalyst · readout
Phase 2 obesity readout expected second half of 2024.
Expected: Sep 1, 2024 – Dec 31, 2024
Catalyst details
- Type
- readout
- Status
- pending
- Date precision
- window
- Confidence
- company guidance
- Asset
- GSBR-1290
- Company
- Structure Therapeutics
Dependencies
- trial-11
Source wording
“Phase 2 obesity readout expected second half of 2024.”
Sources
- registryprimary record
A study to evaluate safety, tolerability, PK/PD of AMG 133 in adults with obesity
Amgen Inc. · ClinicalTrials.gov · Apr 4, 2018 · NCT03548935